EUR-Lex Access to European Union law

Back to EUR-Lex homepage

This document is an excerpt from the EUR-Lex website

Document 62021TB0632

Case T-632/21: Order of the General Court of 1 March 2022 — Agreiter and Others v Commission (Action for annulment — Medicinal products for human use — Amendment of the conditional marketing authorisation for Spikevax, a medicinal product for human use — COVID-19 mRNA Vaccine (nucleoside modified) — No interest in bringing proceedings — Lack of direct concern — Lack of individual concern — Inadmissibility)

OJ C 198, 16.5.2022, p. 35–35 (GA)
OJ C 198, 16.5.2022, p. 50–51 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

16.5.2022   

EN

Official Journal of the European Union

C 198/50


Order of the General Court of 1 March 2022 — Agreiter and Others v Commission

(Case T-632/21) (1)

(Action for annulment - Medicinal products for human use - Amendment of the conditional marketing authorisation for Spikevax, a medicinal product for human use - COVID-19 mRNA Vaccine (nucleoside modified) - No interest in bringing proceedings - Lack of direct concern - Lack of individual concern - Inadmissibility)

(2022/C 198/74)

Language of the case: German

Parties

Applicants: Karin Agreiter (Merano, Italy) and the 33 other applicants whose names are listed in the Annex to the order (represented by: R. Holzeisen, lawyer)

Defendant: European Commission (represented by: L. Haasbeek and B.-R. Killmann, acting as Agents)

Re:

By their action under Article 263 of the TFEU, the applicants seek annulment of Commission Implementing Decision C(2021) 5686 final of 23 July 2021 amending the conditional marketing authorisation for ‘Spikevax’ — COVID-19 mRNA Vaccine (nucleoside modified), a medicinal product for human use granted by Implementing Decision C(2021) 94 final of 6 January 2021.

Operative part of the order

1.

The action is dismissed as inadmissible.

2.

There is no longer any need to adjudicate on the application for leave to intervene submitted by Moderna Biotech Spain SL.

3.

Ms Karin Agreiter and the other applicants whose names are listed in the Annex shall pay the costs.

4.

Moderna Biotech Spain shall bear its own costs related to the application for leave to intervene.


(1)  OJ C 471, 22.11.2021.


Top